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Abstract: Near-infrared dyes can be used as theranostic agents in cancer management, based 
on their optical imaging and localized hyperthermia capabilities. However, their clinical trans-
latability is limited by issues such as photobleaching, short circulation times, and nonspecific 
biodistribution. Nanoconjugate formulations of cyanine dyes, such as IR820, may be able to 
overcome some of these limitations. We covalently conjugated IR820 with 6 kDa polyethylene 
glycol (PEG)-diamine to create a nanoconjugate (IRPDcov) with potential for in vivo applica-
tions. The conjugation process resulted in nearly spherical, uniformly distributed nanoparticles 
of approximately 150 nm diameter and zeta potential -0.4±0.3 mV. The IRPDcov formulation 
retained the ability to fluoresce and to cause hyperthermia-mediated cell-growth inhibition, with 
enhanced internalization and significantly enhanced cytotoxic hyperthermia effects in cancer cells 
compared with free dye. Additionally, IRPDcov demonstrated a significantly longer (P0.05) 
plasma half-life, elimination half-life, and area under the curve (AUC) value compared with 
IR820, indicating larger overall exposure to the theranostic agent in mice. The IRPDcov conjugate 
had different organ localization than did free IR820, with potential reduced accumulation in the 
kidneys and significantly lower (P0.05) accumulation in the lungs. Some potential advantages 
of IR820-PEG-diamine nanoconjugates may include passive targeting of tumor tissue through 
the enhanced permeability and retention effect, prolonged circulation times resulting in increased 
windows for combined diagnosis and therapy, and further opportunities for functionalization, 
targeting, and customization. The conjugation of PEG-diamine with a near-infrared dye pro-
vides a multifunctional delivery vector whose localization can be monitored with noninvasive 
techniques and that may also serve for guided hyperthermia cancer treatments.
Keywords: fluorescent imaging, hyperthermia, image-guided therapy, nanotechnology
Introduction
The development of multifunctional agents for cancer management is a rapidly growing 
field that can result in improved diagnosis and therapy for patients with cancer. The 
use of multifunctional modalities that possess diagnostic and therapeutic properties, 
referred to as theranostics, enables a combined approach to detection and treatment.1–6 
One of the main challenges in combining early diagnosis and therapy is that imaging 
and therapeutic probes are typically different in terms of selectivity and biodistribution.7 
This complicates the process of monitoring responses to treatment, which in turn 
creates difficulties in planning, timing, and assessing the success of interventions. 
In a multifunctional agent, the ability to follow the distribution of an agent in vivo, 
thanks to its imaging capabilities, enables the localization of the target site, which can 
be followed by the activation of the therapeutic modality once the agent has reached 
its desired destination. This ensures that therapy occurs at the desired site and at the 
appropriate time. Multifunctional formulations can also allow real-time monitoring 
of the effect of therapy. By combining both therapy and diagnostic capabilities into 
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a single platform, theranostic agents provide clinicians with 
a multipurpose tool that can be used to detect, image, treat, 
and monitor therapeutic response over time.8 As a result, 
clinicians can implement therapy at an earlier stage, as well 
as achieve increased safety, sensitivity, and efficacy in het-
erogeneously natured diseases, such as cancer.8,9
Near-infrared (NIR) dyes can be used as theranostic 
agents in cancer management, based on their optical imaging 
and localized hyperthermia capabilities; however, they have 
important limitations in their applicability for theranostic use, 
especially in terms of photobleaching, in vivo instability, 
and nonspecific biodistribution.10 Our group has studied the 
properties of the cyanine dye IR820, and we provided the 
first detailed report of its potential for use in theranostics.11 
IR820 is structurally similar to indocyanine green (ICG), 
which is a clinically approved cyanine dye, but IR820 has 
improved in vitro and in vivo stability. Our prior work has 
shown that IR820 is a feasible agent in experimental models 
of imaging and hyperthermia, and could be an alternative to 
ICG when greater stability, longer image collection times, 
or more predictable peak locations are desirable.11 Our group 
has also developed and characterized several formulations 
for combined chemotherapy, imaging, and hyperthermia, 
using chemotherapy agents and NIR dyes.12,13
Several recent studies have applied IR820 dye or con-
jugates of the dye for in vivo applications. Prajapati et al 
used IR820 as a blood pool contrast agent to image tissue 
injuries and tumors in mice.14 Pandey et al conjugated IR820 
with a photodynamic therapy drug and studied the result-
ing conjugate in mice, with IR820 being used exclusively 
for its imaging role.15 Masotti et al conjugated IR820 with 
polyethylenimine (PEI) for DNA binding applications and 
in vivo imaging.16 Thierry et al17 prepared poly(allylamine 
hydrochloride)-poly(acrylic acid)-coated magnetic iron oxide 
and gold nanoparticles, which were loaded with cisplatin as 
well as with a conjugate of IR820 and PEI, following the 
work done by Masotti et al. None of these studies exploited 
the inherent ability of IR820 to be used as a dual imaging 
and hyperthermia agent. Our group has developed several 
IR820-based theranostic formulations, including IR820-
loaded polymeric nanoparticles as well as IR820-chitosan 
conjugates and ionic IR820 polyethylene glycol (PEG)-
diamine conjugates, and we have characterized the imaging 
and hyperthermia capabilities of these agents.18–21
Based on its optical and hyperthermia-generation proper-
ties, IR820 is a promising theranostic agent; however, clinical 
translation of NIR-imaging and hyperthermia approaches in 
cancer must overcome the challenges presented by free-dye 
formulations, in terms of plasma circulation times and non-
specific biodistribution. The creation of nanoformulations of 
IR820 provides some opportunities to improve in vivo stabil-
ity and target delivery. Nanosize therapeutic and diagnostic 
agents can be tailored to a specific application by manipu-
lating their size, shape, surface characteristics, and other 
physiochemical properties. They are also less susceptible to 
reticuloendothelial system clearance and have better pen-
etration into tissues and cells than do larger size agents,22,23 
and passive targeting to tumor sites can be achieved by the 
enhanced permeability and retention effect (EPR).24
We chose to conjugate IR820 with PEG because the 
presence of PEG in nanoformulations can reduce immune 
interactions and result in improved plasma circulation times.25 
Longer exposure to the theranostic agent provides a wider 
window of opportunity for diagnosis and therapy, and allows 
more flexibility in terms of the timing of one with respect to 
the other, as needed for a specific application. Additionally, 
PEG can be used as a linker to conjugate other moieties and 
impart new functionality, such as specific targeting. Covalent 
attachment of PEG does not affect side chain properties in 
solution so that formulations covalently bound to PEG will 
maintain their functionality.26,27
Our group previously reported the formulation of 
ionic IR820-PEG-diamine nanoconjugates, which showed 
enhanced cellular internalization in cancer cells for imag-
ing purposes compared with the free dye, and significantly 
enhanced hyperthermia-mediated cytotoxicity in MES-SA 
and MES-SA/Dx5 (Dx5) cancer cells compared with the 
hyperthermia achieved using free dye.21 Although promising, 
the ionic nanoconjugates only improved on the stability of the 
free dye for up to 4 hours in a phosphate buffer. Given that 
IR820 retained its ability to generate heat and fluoresce when 
interacting in close proximity with PEG as part of an ionic 
formulation, we hypothesized that creating a covalent formu-
lation could further improve on the stability of the lattice and, 
in turn, result in nanosize conjugates that might be used in 
in vivo applications with improved pharmacokinetic profiles 
compared with the free dye, while retaining its theranostic 
properties. Thus, we prepared and characterized covalent 
conjugates of IR820 and PEG-diamine (IRPDcov).
The size and surface morphology of these nanoconju-
gates were characterized by transmission electron micros-
copy (TEM), conjugation was confirmed by proton nuclear 
magnetic resonance (1H NMR), and the optical properties 
in solution were studied using spectrofluorometry and spec-
trophotometry. We explored possible applications through 
in vitro experiments with three different human cancer cell 
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lines (MES-SA, Dx5, and SKOV-3) to investigate the fea-
sibility of using the nanoconjugates as imaging agents and 
to determine whether this formulation retained the ability 
to induce hyperthermic cell killing. Finally, we performed 
pharmacokinetics and biodistribution studies in mice to 
compare IRPDcov, free IR820 and ICG, and to determine 
whether the nanoconjugates show an advantage with respect 
to free-cyanine dyes in terms of in vivo applications.
Methods
Nanoconjugate preparation
PEG-diamine (6 kDa), IR820, methanol, dimethylsulfoxide 
(DMSO) (99.9% reagent grade), and triethylamine were 
purchased from Sigma-Aldrich Corp., (St Louis, MO, USA). 
A mixture of PEG-diamine (6 kDa, 30 mg/5 mL) and IR820 
(9.4 mg/5 mL) in aprotic methanol was refluxed for 4 hours in 
the presence of distilled triethylamine (2 eq). The molar ratio 
was 1:2, PEG-diamine:IR820, based on available functional 
groups (two amines in PEG-diamine and one chloro group 
in IR820). The reaction scheme (Figure 1) involves cova-
lent attachment of the amine group in PEG-diamine to the 
cyclohexene in IR820 at the chloro-substituted position via 
nucleophilic substitution, with displacement of the chlorine 
atom and production of triethylamine hydrochloride. After 
the reaction progressed to completion, the sample was con-
centrated, and the residue was dissolved in 5 mL of water, 
followed by dialysis against water, using a molecular weight 
cutoff (MWCO) 3.5 kDa, for 24 hours. The nanoconjugates 
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Figure 1 reaction scheme and formulation of covalent Ir820-Peg-diamine nanoconjugate (IrPDcov).
Abbreviations: IrPDcov, covalent conjugates of Ir820 and Peg-diamine; Peg, polyethylene glycol; Tea, triethylamine.
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were freeze-dried (FreeZone Plus 6 Liter Cascade Console 
Freeze Dry System; Labconco Corp., Kansas City, MO, 
USA) for 24 hours and stored in powder form at 4°C for 
further use. The choice of 6 kDa PEG-diamine was based on 
the criteria of resulting nanoparticle size, nanoparticle charge, 
reduced steric hindrance, and conservation of fluorescent 
and hyperthermic properties of the dye once combined with 
PEG-diamine.
Nanoconjugate characterization
Freeze-dried IRPDcov particles were resuspended in distilled 
water and later dropped onto a copper grid and dried at room 
temperature. The surface morphology of the samples was 
observed under a TEM (CM 200; FEI, Hillsboro, Oregon, 
USA) operated at 200-keV pulse at different resolutions. The 
nanoconjugate zeta potential was measured using a Zetasizer 
Nano ZS (Malvern Instruments, Malvern, UK) employing 
a nominal 5 mW helium–neon (He Ne) laser operating at 
633 nm wavelength. The scattered light was detected at a 
135° angle. The refractive index (1.33) and the viscosity 
(0.89 cP) of ultrapure water at 25°C were used for mea-
surements. For 1H NMR measurements, samples of IR820, 
PEG-diamine, and IRPDcov were dissolved in deuterated 
methanol. The 1H NMR spectra were recorded on a 400 MHz 
Avance Bruker NMR spectrometer (Bruker Corp., Billerica, 
MA, USA), using 240 scans. Acquired data was processed 
and analyzed using MestReNova software. Chemical shifts 
were reported in parts per million (ppm) for 1H NMR on 
a δ scale based on the deuterated methanol solvent peak 
(δ =3.31 ppm) as an internal standard.
Dye content determination
The IR820 content in the freeze-dried nanoconjugates 
was determined by dissolving a known amount of sample 
in DMSO, sonicating to ensure complete dissolution, and 
performing serial dilutions in the fluorescence linear range. 
Sample fluorescence was measured at peak emission after 
785 nm excitation, with a FluoroLog®-3 spectrofluorometer 
(Horiba Jobin Yvon, Kyoto, Japan), under constant operat-
ing conditions. The amount of IR820 in the samples was 
determined from a calibration curve of free IR820 in DMSO 
after 785 nm excitation, using blank subtraction.
characterization of absorption 
properties
We prepared samples of IR820, PEG-diamine, and IRPDcov 
in deionized water at 100 μg/mL concentration and per-
formed serial dilutions in the linear range. The concentration 
of IRPDcov was normalized to dye content. Sample absorp-
tion, from 200 to 900 nm, was measured with a Cary UV 
Spectrophotometer (Agilent Technologies, Santa Clara, 
CA, USA).
Fluorescence spectra and fluorescence 
stability studies
We prepared samples of IR820 and IRPDcov in phosphate-
buffered saline (PBS) buffer, at concentrations in the linear 
range, and measured their baseline fluorescence emission 
profile after 785 nm excitation. Sample emission fluorescence 
was measured from 795 nm up to 850 nm, at 1 nm intervals, 
using the FluoroLog-3 spectrofluorometer. Different aliquots 
from the same sample batch were kept in the refrigerator and 
measured, following the same procedures, for up to 72 hours 
after preparation. The emission peak value was used to 
determine changes from baseline, and the percent remaining 
fluorescence intensity was calculated. Statistical significance 
was determined by comparing percent remaining intensities, 
using a t-test (α =0.05).
cytotoxicity with and without 
hyperthermia
The cytotoxicity of four different treatments (IR820, IRPD-
cov, IR820 plus laser, and IRPDcov plus laser) was studied 
in cancer cell lines MES-SA, Dx5, and SKOV-3, using the 
sulforhodamine B (SRB) colorimetric assay. Cells were 
seeded onto 96-well plates at an approximate density of 
6.2×104 cells/cm2 and incubated overnight for attachment to 
the well, followed by treatment with free IR820 or IRPDcov. 
The SRB assay was performed 24 hours posttreatment to 
determine net cell growth. Tested IR820 concentrations 
ranged from 0 to 5 μM, where IR820 concentration equal 
to zero meant that only DPBS and no drug was added to the 
wells (control group). Tested IRPDcov concentrations were 
normalized to IR820 content in the particles so that the treat-
ments were equivalent to tested concentrations of free dye.
In order to test the effect of hyperthermia, some of the 
cells were incubated for 1 hour with one of the following 
treatments: 5 μM IR820, IRPDcov at concentrations equiva-
lent to 5 μM of IR-820, or only cell medium. These cells were 
then exposed to 808 nm laser illumination for 3 minutes, 
and the SRB assay was performed 24 hours postlaser treat-
ment. Temperature was measured with a thermocouple, and 
experimental wells were separated from each other by at 
least one empty well in all directions to avoid cross-effects. 
Net growth values were calculated by normalizing the data 
from each treatment to the growth of the control cells, which 
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were not exposed to IR820, IRPDcov, or laser. Statistical 
significance (P0.05) was identified by one-way analysis 
of variance (ANOVA) for the difference among groups at 
the same treatment concentration, and between each group 
and the control group.
cellular imaging
Lysine-coated coverslips were placed in each well of a 24-well 
plate. MES-SA, Dx5, and SKOV-3 cells were seeded on the 
coverslips at a density of 5.2×104 cells/cm2, 5.2×104 cells/cm2, 
and 2.6×104 cells/cm2, respectively, in McCoy’s 5A medium 
supplemented with 10% fetal bovine serum (FBS) and 1% 
penicillin, and were grown overnight for attachment. The next 
day, the cell medium was removed and replaced with 5 μM 
IR820 or equivalent free-dye content of IRPDcov. Cells were 
incubated in the dark at 37°C for 4 hours and then washed 
three times with Dulbecco’s phosphate-buffered saline 
(DPBS). Then the cells were fixed with 4% formaldehyde for 
15 minutes at 37°C, followed by washing three times with 
DPBS. The coverslips were then removed and mounted on 
glass microslides with antifade reagent/mounting medium 
mixture. The cells were then examined by fluorescence 
microscopy (Olympus IX81; Olympus Corporation, Tokyo, 
Japan) with a 60× water-merged objective. The fluorescence 
was imaged at λ
ex
 (775 nm), λ
em
 (845 nm), with an exposure 
time of 4,000 ms, which is well below the 20,000 ms threshold 
for autofluorescence for this wavelength. A charge-coupled 
device (CCD) camera was used to capture the signals, and 
the images were software-merged with pseudo color. The 
fluorescence microscope settings were kept the same through-
out the experiment. The acquired fluorescence images were 
processed by MATLAB® (The MathWorks Inc., Natick, MA, 
USA) to calculate the image ratio (R). First, the intensity 
of each pixel was background-subtracted, and a region of 
interest was defined as being composed of any pixels with 
above-background intensity values (defined as an intensity of 
at least two out of a 255 scale after background subtraction). 
The ratio R was then determined by normalizing the total pixel 
intensity of this region of interest to its total area.
animal study design
All animal protocols were approved by the Florida Inter-
national University Institutional Animal Care and Use 
Committee. Thirty-six healthy ND4 Swiss Webster outbred 
mice, weighing between 25 and 30 grams, were purchased 
from Harlan Laboratories (Indianapolis, IN, USA), housed 
under a 12-hour light/dark cycle and fed ad libitum. Mice 
were randomly assigned to one of twelve groups (n=3) based 
on optical agent (ICG, IR820, or IRPDcov) and time point 
of data collection after injection (15 minutes, 30 minutes, 
60 minutes, and 24 hours). Solutions for injection were pre-
pared based on a 0.24 mg/kg dose of free dye,28 which in the 
case of IRPDcov, was based on conjugate dye content.
For time groups in the range of minutes, mice were 
injected with intraperitoneal (IP) pentobarbital (40 mg/kg for 
initial anesthesia during imaging, and an additional 60 mg/kg 
for euthanasia after imaging was completed). The animals 
were shaved, placed supine on the imaging setup described 
in the “In vivo imaging techniques” section below, injected 
through the tail vein with their assigned agent, and imaged. At 
the predetermined time point, a blood sample was obtained, 
under anesthesia, by heart puncture into the ventricle, and the 
animal was then euthanized by removal of the heart.
For mice in the 24-hour groups, each animal was anes-
thetized with 40 mg/kg of IP pentobarbital, injected with the 
assigned agent, and imaged. These mice were then returned to 
their cage alive until the 24-hour time point. After 24 hours, 
they were again anesthetized with pentobarbital, and imaging 
was performed under the same operating conditions. After 
imaging, a blood sample was obtained by heart puncture 
while under anesthesia, and the animals were euthanized by 
removal of the heart. Organs were carefully harvested for 
imaging and subsequent homogenization and dye extraction 
in DMSO.
In vivo imaging techniques
An imaging system consisting of a Sanyo DL 7140-201S 
laser (80 mW, 785 nm) and a Retiga 1300 CCD camera was 
used. The entire setup was covered by BK5 blackout material. 
The power at the imaging plane ranged from 0.1–0.5 mW. 
An image of the mouse was obtained under white light illu-
mination to determine the position of the target and to focus 
the camera before dye injection. Then, the laser was turned 
on, and another image was taken prior to dye injection, to 
establish background. Laser current was set to 60 mA. After 
the white and background images were obtained, the dye 
solution was injected through the tail vein. The camera started 
recording immediately before the injection, and 10-second 
exposure images of the abdomen were recorded in series, 
using QCapture Pro software, for at least 10 minutes. The 
same procedures were followed for 24-hour imaging, except 
that a still picture was taken rather than serial images.
Plasma and organ sample processing
Plasma and organ sample processing followed the proce-
dures described by other researchers who have performed 
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biodistribution studies of NIR dyes and related compounds.29,30 
In the case of blood samples, immediately after collection, 
the samples were centrifuged two times for 3 minutes at 
12,000 rpm, to extract plasma. Plasma samples were then 
incubated in DMSO (1:50 [plasma:DMSO]) in glass vials 
covered with aluminum foil for 30 minutes and centrifuged 
again. The resulting supernatant was used to perform spectro-
fluorometric measurements of dye concentration in plasma, 
using a previously created calibration curve of IR820 or ICG 
in DMSO at 785 nm excitation.
For organ samples in the 24-hour groups, organs were 
carefully dissected and placed in black-coated Petri dishes 
for imaging. Fluorescent organs were then cut into small 
pieces using a scalpel, placed in preweighed glass vials, 
and homogenized. Then, 5 mL of DMSO was added for dye 
extraction. Samples were incubated in DMSO for 4 hours 
and centrifuged at 9,000 rpm for 15 minutes. The super-
natant was used to perform spectrofluorometric measure-
ments of dye content, using a previously created calibration 
curve of IR820 or ICG in DMSO at 785 nm excitation. 
To report the data, organ dye content was normalized to 
organ mass.
Pharmacokinetic analysis of plasma data
Dye concentration in plasma obtained from spectrofluo-
rometer measurements was averaged for each group, and 
the average concentration for each time point was entered 
into MATLAB. The initial concentration (concentration at 
injection) for an average 25 g mouse was estimated to be 
approximately 4 μg dye/mL in plasma. Using the Curve 
Fitting Tool in MATLAB, average data points at 0, 15, 30, 
60 minutes, and 24 hours were fit to biexponential curves 
via a least squares algorithm to represent a two-compartment 
model. The resulting biexponential fit equations were used 
to determine the half-lives of distribution and elimination, 
the area under the pharmacokinetic curve (AUC), the mean 
plasma residence time, and the clearance rate. The mean 
residence time in plasma, t
p
, is the average time spent by 
the agent of interest in plasma, and is given, in its simplest 
expression, by:
 
Mean plasma 
residence time
Area under curve
Initial co
= = t  
p ncentration 
 (1)
The total body clearance rate (ie, volume of agent cleared 
from the body per unit time) is given by:
 Total body clearance rate
Dose
Area under curve
=  (2)
Based on the preceding calculations, we compared the 
IRPDcov, IR820, and ICG pharmacokinetic parameters, 
using one-way ANOVA (P0.05) followed by Bonferroni 
post hoc test.
Results and discussion
characterization of IrPDcov
IRPDcov size and morphology were characterized using 
TEM, which showed nearly spherical, uniformly distrib-
uted nanoconjugates of approximately 150 nm diameter 
(Figure 2). The zeta potential of IRPDcov was -0.4±0.3 mV 
due to charge neutralization during formulation. The 
nanoconjugates are soluble in aqueous solution, and PEG-
mediated steric repulsion assists in preventing the formation 
of aggregates.
0.5 µm 50 nm
Figure 2 TeM images of IrPDcov.
Abbreviations: IrPDcov, covalent conjugates of Ir820 and Peg-diamine; Peg, polyethylene glycol; TeM, transmission electron microscopy.
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Particle yield was 74% for a 6kDa PEG-diamine formula-
tion. Samples of IRPDcov in deuterated methanol were also 
analyzed by 1H NMR, which confirmed conjugate formation. 
The conjugate 1H NMR spectrum contained peaks contrib-
uted both from IR820 and PEG-diamine, which suggested 
that we had indeed prepared the conjugate. Any unreacted 
IR820 would have been removed during the dialysis process, 
so the presence of aromatic peaks (in the region between 
7 and 9 ppm) indicated that both IR820 and PEG-diamine 
were present in the conjugated structure. Additionally, the 
spectrum of the conjugate showed an upfield proton shift in 
the 7.5–8.5 ppm area compared with the spectrum of free 
IR820. This is likely explained by the fact that conjugation 
replaces the electron-withdrawing chlorine group in IR820 
with an electron-releasing amine group from PEG-diamine, 
and indicates that the covalent linkage between IR820 and 
PEG-diamine was successful. IRPDcov fluorescent dye 
content was determined by spectrofluorometry to be approxi-
mately 0.113 mg IR820/mg IRPDcov.
absorbance studies
The ultraviolet (UV)-visible spectra of IR820, PEG-diamine, 
and IRPDcov are shown in Figure 3. Concentrations of 
PEG-diamine and IR820 were chosen based on molar ratios 
used in the formulation of the nanocomplexes, and IRPDcov 
concentration was chosen to approximately match the concen-
tration of the IR820 solution, given the previously estimated 
dye content (0.113 mg IR820/mg IRPDcov). IRPDcov dis-
played a bathochromic main absorption peak shift compared 
with IR820 (IRPDcov λ
max
 =702 nm, IR820 λ
max
 =688 nm) as 
well as a shift in the secondary absorption peak (located at 
836 nm for IRPDcov versus 815 nm for IR820). These shifts 
can be attributed to the formation of an extended π system by 
the conjugation process. There was also an overall broadening 
of the spectral profile. Increased absorption and scattering 
within the environment of the nanoconjugate may explain 
the spectral observations. There were no peaks above 0.01 
AU between 200 and 900 nm for PEG-diamine at 24 μg/mL. 
The free-dye spectrum showed a maximum peak at 688 nm, 
with almost the same absorption intensity as the IRPDcov 
solution, confirming our dye content determination.
Fluorescence properties of IrPDcov  
and fluorescence stability studies
A representative fluorescence emission spectrum of IRPDcov 
after 785 nm excitation is shown in Figure 4, along with the 
Wavelength (nm)
1.0
0.8
0.6
0.4
0.2
0.0
200 400 600 800 1,000
815 nm
688 nm
IR820 6.25 µg/mL
IRPDcov 6.25 µg/mL dye content
PEG-diamine 24 µg/mL
702 nm
836 nm
A
U
Figure 3 absorption spectra of Ir820 (solid black), IrPDcov (dashed black), and Peg-diamine (gray) in deionized water.
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corresponding profile for IR820 at comparable dye content. 
After 785 nm excitation, the peak emission for IRPDcov was 
located at 822 nm, with fluorescence intensity 6% smaller 
than IR820. The slight reduction in fluorescence intensity 
may have been due to increased scattering within the struc-
ture or to secondary self-absorption due to the presence of 
the 836 nm absorption peak. IRPDcov and IR820 solutions 
in buffer were measured up to 72 hours after preparation, to 
determine the percent remaining fluorescent intensity com-
pared with baseline. Samples were kept at 4°C, in the dark. 
The decrease in fluorescence from baseline after 72 hours was 
significantly lower for IRPDcov (39.9% decrease) compared 
with IR820 (80% decrease) (P0.05). This indicates that 
covalent conjugation provides significant stabilization to 
the dye, likely as a result of increased rigidity of the IR820 
molecule from its incorporation into the nanoconjugate lat-
tice, which would reduce intermolecular IR820 aggregation. 
PEG-mediated steric hindrance may also have played a role 
in preventing aggregation of IR820 molecules and the sub-
sequent degradation process. The enhanced preservation of 
fluorescence properties also indicates that the conjugate was 
stable as formulated for at least 72 hours, based on the large 
differences in fluorescence observed between the conjugate 
and free-dye samples after that time period.
cellular imaging
Figure 5 shows fluorescence microscopy images of Dx5, 
SKOV-3, and MES-SA cell lines after 4 hours incubation 
at 5 μM concentration of IR820 and IRPDcov at equivalent 
dye content. This concentration was chosen based on our 
previous cellular studies with IR820. In all three cell lines, 
intense fluorescence was observed inside the cells after 
4-hour incubation with IR820 or IRPDcov, indicating that 
both the free dye and the nanoconjugates were capable of 
entering the cells. However, the images taken after IRPDcov 
incubation showed higher normalized intensity ratios than 
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did those taken after incubation with equivalent concentra-
tions of IR820, especially in Dx5. Normalized intensity 
ratios were 1.8 times larger for IRPDcov than for IR820 in 
Dx5, 1.4 times larger in MES-SA, and 1.2 times larger in 
SKOV-3. PEG can enhance cell membrane interaction and 
increase cell internalization, by osmoelastic coupling and 
formation of PEG-induced fusion vesicles.31,32 In the case 
of IRPDcov, this may be one of the contributing factors to 
enhanced internalization.
cytotoxicity and hyperthermia studies
When excited with 808 nm light, IR820 spontaneously 
releases a significant amount of energy in the form of heat. 
In response to photon excitation, electrons in the IR820 
molecule transition to different energy levels, and the sub-
sequent process of relaxation results in heat dissipation. We 
tested IRPDcov to determine whether the dye in nanocon-
jugate form was still able to generate heat upon exposure to 
an 808 nm NIR laser. At a laser fluence rate of 8 W/cm2, a 
solution of 0.038 mg/mL IRPDcov (containing 5 μM IR820) 
caused an increase in temperature from 37°C to 42.2°C 
after 3 minutes of exposure, demonstrating that covalent 
binding of IR820 did not interfere with its heat generation 
properties. This temperature is in the moderate hyperthermia 
range (41°C–43°C), which can cause significant tumor cell 
growth inhibition but does not greatly affect healthy cells. 
It has been reported that cancer cells have mechanisms that 
inhibit oxidative metabolism that are specifically activated by 
temperatures in this range.33–36 We also tested PEG-diamine 
by itself, which did not result in significant changes in tem-
perature after 3-minute laser exposure compared with wells 
containing medium only. Therefore, the IR820 component 
of the nanoconjugates was responsible for hyperthermia 
generation.
SKOV-3, Dx5, and MES-SA cells were chosen to study 
the cytotoxic effect of IR820 and IRPDcov on tumor cells, 
with and without hyperthermia. Figure 6 shows net cell 
growth following incubation with IR820 or IRPDcov, with or 
without exposure to laser, for SKOV-3, Dx5, and MES-SA. 
All groups were normalized to the control group not exposed 
to dye or laser. From our previous studies, we determined 
that laser exposure by itself or PEG-diamine by itself did 
not cause any significant effect on cell growth for any of 
the three cell lines.21
Without laser, IRPDcov demonstrates toxicity compa-
rable to the free dye. There was no significant toxicity in 
SKOV-3 or Dx5 compared with the control group, which 
was not exposed to IRPDcov or IR820, and there was a 
slight growth inhibition in MES-SA cells for either treat-
ment, consistent with our previous reports for IR820 and 
IR820 conjugates.11,21 There was no significant difference in 
net cell growth between the IR820 group and the IRPDcov 
group without laser exposure for any cell line, indicating that 
IRPDcov can be safely used up to at least 5 μM.
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Figure 5 cellular imaging of Dx5 (A and D), Mes-sa (B and E), and sKOV-3 cells (C and F) after a 4-hour incubation with 5 μM dye content of Ir820 (top) or IrPDcov 
(bottom); 60×, exposure time 4,000 ms, compared against the pixel intensities scaled from 0 to 255.
Abbreviations: IrPDcov, covalent conjugates of Ir820 and Peg-diamine; Peg, polyethylene glycol.
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When exposed to laser, cell growth was significantly 
inhibited in all three cell lines by both IR820 and IRPDcov. 
In MES-SA and Dx5 cell lines, exposure to IRPDcov with 
hyperthermia resulted in significantly higher cytotoxicity 
(P0.05) compared with IR820. In the case of MES-SA, 
IRPDcov plus laser resulted in cell killing, whereas IR820 
plus laser caused only cell growth inhibition. In SKOV-3 
cells, IRPDcov with hyperthermia produced higher cyto-
toxicity than did free dye but not enough to reach statistical 
significance. Based on the cell imaging results displayed in 
Figure 5, there may have been a larger degree of internaliza-
tion for IRPDcov than for free dye. Although this is not a 
direct measurement of uptake, the results of the image analy-
sis seem to indirectly indicate that there may have been higher 
amounts of conjugate than free dye present in the cells. This 
would be consistent with the increased cytotoxicity effect of 
the hyperthermia treatment that can be observed in Figure 6. 
Enhanced internalization would result in larger accumulation 
of the dye inside the cell and an accentuated damaging effect 
of temperature increases. This seems to be most apparent in 
MES-SA cells, where treatment with IRPDcov plus laser 
resulted in a cell-killing effect.
It is interesting to note that the hyperthermia-enhanced 
cytotoxic effect versus free dye reached statistical signifi-
cance in MES-SA and Dx5 cell lines but not in SKOV-3. 
Other researchers have reported that SKOV-3 cells have 
inherent thermotolerance, which could be related to 
their characteristic p53 gene mutation.37 Hyperthermia-
induced cytotoxicity is controlled by both p53-dependent 
and -independent pathways.38–40 Based on existing knowl-
edge, thermosensitivity and thermotolerance depend on an 
array of biological, genetic, and environmental factors so 
that a specific cause for SKOV-3 thermotolerance within the 
context of our studies cannot be determined.
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animal and organ imaging
Figure 7 shows representative images obtained from ICG, 
IR820, and IRPDcov animals 15 minutes and 24 hours after 
injection. These images prove that IRPDcov can be used for 
in vivo imaging and that it provides an imaging signal compa-
rable to that of IR820. The signal ratio for ICG at 15 minutes 
after injection was higher than that of IR820 or IRPDcov; 
however, by 24 hours, the intensity of ICG had dropped 
significantly in comparison with the other two agents. 
The 24-hour ICG signal also seemed to be located in 
the lower abdomen, instead of in the liver region as is the 
case for the other two agents. Organ images obtained after 
24 hours demonstrate a very different biodistribution for 
ICG compared with the other two agents. Figure 8 provides a 
qualitative comparison of organ signals for IRPDcov, IR820, 
and ICG, and Table 1 summarizes the organ signal intensity 
per unit area ratios for each dye.
The information obtained from the ratio data indicates 
that the biodistribution of IRPDcov, IR820, and ICG shows 
a different pattern between agents 24 hours after intravenous 
(IV) injection. Although an ICG signal was still present in 
the liver, the ratio was significantly lower (P0.05) than for 
IR820 or IRPDcov. The amount of ICG present in the kid-
neys and the lungs was also significantly smaller (P0.05) 
than for the other two agents. In the case of the intestines, 
a higher signal was observed for ICG than for IR820 or 
IRPDcov; however, the effect did not reach statistical sig-
nificance, due to the large standard deviation for the ICG 
measurements in the intestines. We expect that intersubject 
variability in intestinal motility rates would affect ICG more 
markedly, given that most of the dye is being eliminated via 
the gastrointestinal tract at the 24-hour time point.
In the case of IR820, a strong signal was observed in 
the liver, kidneys, and lungs, with a small signal in the 
intestines. IRPDcov showed a strong signal in the liver, 
some signal in the kidneys, and a small signal in lungs 
and intestines. Statistical analysis comparing IR820 and 
IRPDcov showed that there were no differences in liver or 
intestinal image ratios. There was a significant difference 
(P0.05) in lung image ratios, with IRPDcov showing a 
smaller signal ratio than IR820. This possibly indicates 
that the nanoformulation was able to escape detection by 
alveolar macrophages, thanks to the presence of PEG, 
which reduces binding to serum proteins.41 In the kidneys, 
the IRPDcov signal was smaller than that of IR820, but 
the difference did not reach statistical significance. There 
may be a somewhat smaller degree of elimination of 
IRPDcov through the kidneys, which would be consistent 
with the expectation that the larger size of the conjugate 
compared with the free dye would result in decreased renal 
clearance (based on a low molecular size cutoff for renal 
excretion),42 as well as the fact that the presence of PEG 
could result in reduced reticuloendothelial system uptake. 
However, the small number of subjects in our study may 
not provide enough sensitivity to detect a significant dif-
ference. Another reason for the lack of significance could 
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be variability in renal elimination rates between subjects. 
Additionally, imaging ratios may not be sensitive enough 
to detect quantitative differences.
From these images, we can conclude that there are clear 
differences in the biodistribution patterns of ICG versus 
IRPDcov and IR820, with ICG being more rapidly cleared 
from major organs than the other two agents, and primar-
ily localizing in fecal elimination pathways by 24 hours. 
The difference in behavior was probably due to a much 
faster plasma clearance combined with a high level of ICG 
binding to plasma proteins, faster liver clearance, and loss 
of signal due to poor ICG stability. IR820 and IRPDcov 
provide an advantage in terms of prolonged residence 
times, although for both these agents, the timing of imaging 
would need to be optimized so that the signal is high in the 
target tissue and low in the plasma and nontarget tissue. In 
terms of comparing IRPDcov with IR820, our lung images 
support the hypothesis of reduced mononuclear phagocyte 
system uptake,43 which we can probably owe to the pres-
ence of PEG. However, this is not the only possible factor 
affecting the biodistribution of these conjugates as size 
can also play a significant role in the pharmacokinetics of 
nanoformulations and their uptake by body tissues. For 
instance, particles of sizes larger than 10 nm are unlikely 
to undergo glomerular filtration, and the primary elimina-
tion route for particles that are not excreted through the 
kidneys is the hepatobiliary system,44 consistent with our 
observations.
Organ dye content
Figure 9 shows the average dye content (in μg dye/g tis-
sue) for liver, lungs, kidneys, and intestines 24 hours after 
an IV injection of IRPDcov, IR820, or ICG. The data is 
consistent with our qualitative observations and quantitative 
signal ratios from the optical imaging samples, and provides 
increased sensitivity to detect differences. When we compare 
the results for ICG with those of IRPDcov and IR820, we see 
that organ content was significantly higher in the intestines 
and significantly lower in all other organs. For lungs and 
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Figure 8 Organ images taken 24 hours after IV injection of IrPDcov, Ir820, or Icg compared against the pixel intensities scaled from 0 to 255.
Abbreviations: Icg, indocyanine green; IrPDcov, covalent conjugates of Ir820 and Peg-diamine; IV, intravenous; Peg, polyethylene glycol.
Table 1 signal intensity ratios for liver, lungs, kidneys and intestines 
collected 24 hours after IV injection of IrPDcov, Ir820, or Icg
Image intensity per area, R (1/µm2)
IRPDcov IR820 ICG
liver 6.35±0.44* 6.13±1.44* 0.76±0.35
Lungs** 0.64±0.08* 2.48±0.47* 0.18±0.32
Kidneys 1.34±0.13* 2.95±1.88* 0.20±0.34
Intestines 0.65±0.10 1.00±0.45 2.01±1.43
Notes: Values represent average ± SD. *Significant difference (P0.05) with Icg 
values for the same organ; **significant difference (P0.05) between IrPDcov and 
Ir820 values for the same organ.
Abbreviations: Icg, indocyanine green; IrPDcov, covalent conjugates of Ir820 
and Peg-diamine; IV, intravenous; Peg, polyethylene glycol; sD, standard deviation.
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kidneys, ICG sample readings were at background level. 
When comparing IRPDcov and IR820, the only significant 
difference was a reduced content of IRPDcov in the lungs. 
IRPDcov kidney content was lower than that for IR820, but 
the difference was not significant. This is consistent with 
our observations in the organ imaging studies. The differ-
ence between intestinal uptake of ICG, IRPDcov, and IR820 
became significant once quantitative organ dye content was 
used as a measurement.
Plasma dye concentration
Figure 10 shows the average dye concentration in plasma 
(in μg/mL) for IRPDcov, IR820, and ICG at each of the 
time points under study. We observed significantly higher 
(P0.05) plasma concentrations of IR820 and IRPDcov 
compared with ICG for all time points, with plasma values 
20 times higher for IRPDcov and 10 times higher for IR820, 
at 24 hours. We also found significantly higher (P0.05) 
concentrations of IRPDcov compared with IR820 at the 
30-minute, 60-minute, and 24-hour time points, with plasma 
concentration of IRPDcov double that of IR820 at the 24-hour 
sampling time.
Based on these results, not only were IR820 formula-
tions superior to ICG in terms of plasma concentration 
over time, but we also observed a clear advantage of the 
IRPDcov conjugate over IR820 after initial distribution. 
This validates the theoretical basis for the formulation 
of this conjugate, which relied on the possibility that the 
presence of PEG could contribute to improved plasma con-
centration profiles by reducing detection by macrophages 
and other circulating agents in plasma. IRPDcov is thus 
analogous to other formulations in which the inclusion of 
PEG has provided some stealth characteristics in an in vivo 
environment.45–49
The recovered percent age of injected dose at 24 hours in 
plasma was 3.3% for IRPDcov, 1.7% for IR820, and 0.8% 
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for ICG. If we add these numbers to the percentage values 
of the recovered injected doses found in our organ content 
studies, we reach an overall percentage of 15.1% for IRPD-
cov, 17.7% for IR820, and 2.6% for ICG. In the case of ICG, 
almost the entire injected dose was lost after 24 hours, which 
demonstrates a clear advantage of the IR820 formulations in 
terms of injected dose recovery at this time point. Surpris-
ingly, we did not observe a larger percentage dose recovery 
for IRPDcov compared with IR820. A possible explanation 
may be that the circulating concentration of IRPDcov was 
still double that of IR820 at 24 hours. It is also possible that 
a considerable amount of the conjugate may yet have been 
present in other nonsampled tissues, such as fat, skin, muscle, 
bone, or the lymphatic system.
Pharmacokinetic modeling
Table 2 shows the resulting fitted parameters from a two-
compartment pharmacokinetics model of the IRPDcov, 
IR820, and ICG data, given the biexponential equation: 
 C(t) A e B e
at bt= +− −× ×  (3)
Our results show that both IR820 and IRPDcov demon-
strated significantly longer (P0.05) distribution half-lives, 
longer elimination half-lives, larger AUC, longer plasma 
residence times, and slower body clearance rates than did ICG. 
Although distribution happened quite fast for all agents, the 
ICG distribution half-life was approximately 3.06 minutes, 
whereas the value for IR820 was 13.4 minutes and for 
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IRPDcov was 21.8 minutes. The distribution half-life value 
for ICG is consistent with that previously reported by other 
authors, which has ranged from 2 to 4 minutes.50,51 The cal-
culated elimination half-lives for IRPDcov and IR820, which 
both exceeded 30 hours, were in stark contrast with that of 
ICG, which was 1.85 hours. These values are also well aligned 
with some of the conclusions reached by Prajapati et al who 
estimated that IR820 should have a clearance half-life close 
to that of albumin, which is in the order of 35 hours.14 The 
elimination half-life value we obtained for ICG is consistent 
with literature data as other authors report an elimination 
half-life of over 1 hour at low concentrations.50
Both the distribution and the elimination phases showed 
improved profiles for IR820 formulations compared with 
ICG, in terms of providing a wider time window for thera-
nostic action. As far as the AUC, both IRPDcov and IR820 
were an order of magnitude larger than ICG, indicating an 
increased overall tissue exposure to the theranostic agent. 
Additionally, IRPDcov also showed a significant advantage 
(P0.05) over IR820 for all the above calculated parameters, 
with almost double the AUC and mean plasma residence time 
of IR820, and almost half the clearance rate of IR820. The 
nanoformulation was present in plasma for longer periods of 
time, eliminated more slowly from the body, and the cumula-
tive exposure of body compartments to the conjugate was 
larger than for either of the two free dyes. The time that the 
IRPDcov was bioavailable was also significantly longer as 
the elimination half-life of IRPDcov was 1.16 times longer 
than that of IR820 and 19 times longer than that of ICG, 
whereas the distribution half-life of IRPDcov was 1.6 times 
longer than that of IR820 and seven times longer than that 
of ICG.
Given that the enhanced permeability and retention effect 
is proportional to the time and amount of agent circulating in 
blood,29 we would theoretically expect IRPDcov to result in 
a greater amount of dye accumulated and retained in tumors. 
However, further studies in a tumor-bearing model would be 
needed to explore this possibility.
Other authors have studied the pharmacokinetics of 
nanoformulations, and the general consensus is that nanofor-
mulations may result in improved pharmacokinetic profiles, 
in many cases as a result of stabilization of the drug and 
reduced metabolism and clearance.42 Still, loss of nanocom-
plexes from the circulation can occur by binding to serum 
proteins in the process known as surface opsonization, which 
subsequently causes recognition and removal by circulating 
phagocytes or macrophages.47,52 In the case of PEGylated 
formulations, steric hindrance reduces the degree of protein 
binding, resulting in prolonged circulation times and giv-
ing PEGylated formulations an improved pharmacokinetic 
profile compared with their non-PEGylated counterparts.42,52 
This seems to be applicable to formulations incorporating 
PEG as a conjugated moiety, as was the case of the IRPDcov 
conjugate.
Another consideration which is intimately tied to these 
profiles is the surface charge of the formulation. Our nano-
conjugates were zwitterionic, presenting both positive and 
negative charges and an overall zeta potential approaching 
neutrality. Other authors have found that for other physical 
characteristics being similar, neutral and zwitterionic nano-
formulations exhibit prolonged plasma half-lives and reduced 
clearance compared with largely positive or largely negative 
formulations, which indicates that charge may play a large 
role in maximizing circulation time.53
Nanocomplex size also has an effect on circulation time, 
with particles around 100 nm diameter demonstrating lon-
ger blood circulation profiles than larger or smaller particle 
sizes.42 Liu et al studied the effect of size on biodistribution 
of liposomes and found that sizes between 100 and 200 nm 
were present in circulation for longer times than those 
greater than 250 nm or smaller than 50 nm.54 Given that our 
nanoconjugates were around 150 nm per TEM measurement, 
Table 2 Pharmacokinetic parameters from two-compartment analysis of dye data in mice
IRPDcov IR820 ICG
Model equation based  
on plasma data
c(t) = 3.66×e-1.91t + 0.32×e-0.020t c(t) = 3.83×e-3.12t + 0.1702×e-0.023t c(t) = 3.93×e-13.54t + 0.07×e-0.38t
R2 0.995 0.999 0.999
Distribution half-life, h 0.364±0.006†,†† 0.223±0.003†,†† 0.051±0.001
elimination half-life, h 35.46±0.56†,†† 30.45±0.45†,†† 1.85±0.03
aUc, (μg-h)/ml 7.98±0.13†,†† 4.38±0.07†,†† 0.490±0.007
Mean residence time in plasma, h 1.99±0.03†,†† 1.09±0.02†,†† 0.12±0.002
Total body clearance rate, ml/h 0.75±0.01†,†† 1.37±0.02†,†† 12.25±0.18
Notes: †Significant difference (P0.05) with Icg; ††significant difference (P0.05) IrPDcov vs Ir820.
Abbreviations: aUc, area under the time–concentration curve; Icg, indocyanine green; IrPDcov, covalent conjugates of Ir820 and Peg-diamine; Peg, polyethylene glycol.
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it seems that size was also contributing to their prolonged 
circulation times.
Our analysis is not without possible limitations. First, the 
pharmacokinetic models we used have important assump-
tions, such as uniform distribution, no absorption, rapid 
equilibration before sampling, and no degradation. Uniform 
distribution may be an issue as we know that nanoformula-
tions are distributed to tissues depending on pore size, in 
a different manner than their free-form counterparts.55,56 
In terms of rapid equilibration, others have reported that 
equilibration of injected solutions in mice plasma can be 
assumed to happen within 2 minutes.57 Since our first sample 
was taken at 15 minutes, we can assume that equilibration 
had occurred by that time. Regarding the possibility of deg-
radation into other byproducts, other authors have shown 
that ICG is mostly excreted in its intact form in bile.29 Our 
in vitro studies show that IRPDcov conjugates were very 
stable and retained their characteristics for at least 72 hours 
in PBS. Based on this, we do not expect degradation to be a 
significant concern within the time periods studied in vivo. 
However, the in vivo environment cannot be fully mimicked 
by in vitro conditions, and some in vivo factors, such as 
the presence of plasma proteins, reticuloendothelial system 
scavengers, and metabolism in liver or other tissues, may 
result in aggregation, degradation, or changes in the structure 
of these molecules.
Image-guided therapy using IR820 conjugates shows 
promise for clinical translation as it can be coupled with mini-
mally invasive light delivery techniques, such as endoscopic 
or orthoscopic approaches. Future work will focus on study-
ing the biodistribution of these conjugates in tumor-bearing 
animals in order to determine in vivo tumor uptake, as well 
as on the design and optimization of minimally invasive in 
vivo methods for combined imaging and hyperthermia, pos-
sibly through fiber optic technology.
Conclusion
We successfully prepared nanocomplexes of IR820 and 
PEG-diamine (IRPDcov) and investigated cellular uptake 
and cytotoxicity in cancer cell lines MES-SA, SKOV-3, 
and Dx5. The IRPDcov formulation can potentially provide 
an advantage over the use of free agents by significantly 
enhancing the stability of the NIR dye, increasing cell inter-
nalization, allowing simultaneous colocalization of imaging 
and therapy, and accentuating the cytotoxic effect of hyper-
thermia. IRPDcov can be used for in vitro optical imaging 
of cancer cells as well as in vivo imaging. Biodistribution 
and pharmacokinetic studies of IRPDcov, IR820, and ICG 
in healthy mice show that IRPDcov is a feasible alternative 
to IR820 for in vivo imaging and that it demonstrates an 
improved pharmacokinetic profile over the free-dye form 
as well as over the commonly used NIR dye ICG. IRPDcov 
demonstrated significantly longer distribution and elimina-
tion half-live, longer mean plasma residence time, larger 
overall exposure as indicated by AUC, and slower clearance 
rate compared with either IR820 or ICG. The conjugate has 
different organ localization than free IR820, with potential 
reduced accumulation in the kidneys and significantly lower 
(P0.05) accumulation in the lungs. The nanosize nature of 
our conjugate, as well as surface and charge characteristics 
provided by the presence of PEG, is likely to be responsible 
for these differences. The use of IRPDcov conjugates could 
provide wider in vivo availability windows for theranostic 
applications. Future research will include studies in tumor-
bearing animals, in order to explore the passive targeting 
ability of this formulation as well as to investigate the optimal 
dosage that will provide effective therapeutic hyperthermia 
and imaging in vivo.
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